Drug Database
RA

rabies vaccine (Thrabis)

✓ Approved

Cadila Pharmaceuticals Ltd. · 重组蛋白 · 重组蛋白

什么是 rabies vaccine?

rabies vaccine 是一种重组蛋白,由Cadila Pharmaceuticals Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Thrabis
公司Cadila Pharmaceuticals Ltd.
药物类别重组蛋白, 疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

治疗适应症

rabies vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsRabies✓ Approved

相关研究文献

PubMedThe Pediatric infectious disease journal2026-09-10

Immunogenicity of Single-visit, Two-site Intradermal Pre-exposure Rabies Prophylaxis in Children: A Prospective Interventional Study.

Agarwal Anurag A, Sharma Kanvi K, Mathur Surendra Bahadur SB, Manchanda Vikas V et al.

Rabies remains a major public health concern in endemic countries, particularly among children. Simplified pre-exposure prophylaxis (PrEP) schedules may improve feasibility and access in resource-limited settings and facilitate the integration of rabies vaccination into routine childhood immunization, school-based and community-based vaccination programs in rabies-endemic regions. However, pediatric data on single-visit, 2-site intradermal PrEP regimens remain limited. This study evaluated the immunogenicity and safety of a single-visit, 2-site intradermal rabies PrEP regimen in children 1-18 years of age on days 28 and 180. This prospective single-arm study enrolled healthy children 1-18 years old at a tertiary care center. Participants received a single-visit, 2-site intradermal rabies PrEP regimen with a Vero cell culture rabies vaccine (RABIVAX-S®). Anti-rabies glycoprotein immuglobulin G antibody concentrations were measured using enzyme-linked immunosorbent assay, and rabies virus neutralizing antibody concentrations were estimated by Rapid Fluorescent Focus Inhibition Test at baseline, day 28 and day 180. Participants with rabies virus neutralizing antibody concentrations <0.5 IU/mL at day 28 or day 180 received 2 intradermal booster doses on days 0 and 3 after laboratory results became available and participants returned for follow-up, followed by repeat antibody assessment 7 days after the first booster dose. The primary outcome was seroprotection (≥0.5 IU/mL). Forty-eight children were enrolled, of whom 44 were evaluated on day 28. The enrolled cohort comprised participants 2-15 years old. On day 28, 40/44 (90.9%) achieved protective antibody concentrations (≥0.5 IU/mL). Among 40 participants included in the day 180 analysis, 27 (67.5%) maintained protective concentrations. All participants with insufficient concentrations (n = 4 on day 28, n = 13 on day 180) demonstrated robust anamnestic responses following booster administration, achieving 100% seroprotection within 7 days. The regimen was well tolerated, with only mild local adverse events reported. Single-visit, 2-site intradermal rabies PrEP demonstrated high early seroprotection and preserved immunologic priming despite declining antibody concentrations at 6 months. These findings support further evaluation of simplified pediatric PrEP regimens in larger controlled studies.

PMID 42717284
阅读全文 →
PubMedJournal of medical virology2026-09-10

Development and Epitope Characterization of Monoclonal Antibodies Targeting the Rabies Virus P Protein.

Liang Chao C, Chen Yanhui Y, Liu Hongliang H, Zhou Jingming J et al.

Rabies is a fatal zoonotic disease caused by rabies virus (RABV), resulting in approximately 59,000 deaths annually worldwide and posing a serious threat to public health. The RABV phosphoprotein (P protein) plays crucial roles in viral replication, transcription, and immune antagonism; however, its immunogenic properties have not been fully characterized. In this study, the RABV P protein was expressed in an Escherichia coli expression system and used to immunize mice, resulting in the generation of six P protein-specific monoclonal antibodies (mAbs). Using an overlapping peptide-based truncation strategy, two linear B-cell epitopes were identified: 52DMKRLHLDDEKSSNL66 and 177VAPGPPALEWSATNE191. Alanine-scanning mutagenesis revealed that residues D52, M53, R55, L56, and L58 were critical for the recognition of epitope 52DMKRLHLDDEKSSNL66 by mAbs 2D2 and 18G7. Residues G180, P181, and W186 were essential for recognition of epitope 177VAPGPPALEWSATNE191 by mAbs 3D7, 15D8, 16D3, and 16C6. Notably, although some amino acid residues within epitopes P1-5 and P4-2 exhibited high variability among representative RABV strains, the critical residues recognized by these monoclonal antibodies were highly conserved. These findings provide new insights into the antigenic structure of the RABV P protein and may contribute to future studies on its functional characterization, as well as the development of P protein-based diagnostic reagents and subunit vaccines.

PMID 42720246
阅读全文 →
PubMedFrontiers in immunology2026-09-10

A bivalent oral yeast vaccine displaying Nocardia seriolae FHA and LMBV MCP confers protection in largemouth bass (Micropterus salmoides).

Lu Jianfei J, Gu Boge B, Yu Pengzhen P, Chen Jiong J

Largemouth bass ranavirus (LMBV) and Nocardia seriolae are major pathogens affecting largemouth bass (Micropterus salmoides), causing significant economic losses. In this study, recombinant yeasts expressing the fibronectin-binding protein A (FHA) of N. seriolae or the major capsid protein (MCP) of LMBV were constructed using the yeast surface display (YSD) system. Based on these recombinant strains, a bivalent oral yeast-based vaccine was developed and its protective efficacy was systematically evaluated. Oral administration of the vaccine induced specific antibodies against FHA and MCP in serum, as well as increased the transcription levels of adaptive immune genes (IgM, IgT, MHC-II) and innate immune genes (IL-1β, TNF-α, IFN-1, Mx2) in the hindgut, liver, and spleen. Importantly, the bivalent oral vaccine provided significant protection against both pathogens in largemouth bass, with relative percent survival (RPS) values of 56.7% against N. seriolae and 63.3% against LMBV. Meanwhile, the oral vaccine reduced pathogen loads and alleviated histopathological lesions. In summary, these findings suggest that the bivalent oral vaccine developed in this study could serve as a promising strategy for controlling N. seriolae and LMBV infections in largemouth bass aquaculture.

PMID 42718698
阅读全文 →
PubMedMicrobiology resource announcements2026-09-10

Genomic characterization of the attenuated human cytomegalovirus strain TR-VAC developed for subviral particle vaccine production.

Schmidt Hanno H, Hewel Charlotte C, Büscher Nicole N, Linke Matthias M et al.

We report the complete genome sequence of the attenuated human cytomegalovirus strain TR-VAC, developed for subviral particle vaccine production. Oxford Nanopore duplex sequencing confirmed all engineered modifications, including UL130 repair, UL25 stop codons, ddFKBP insertion, GFP deletion, and retention of the bacterial artificial chromosome backbone, without large-scale structural rearrangements.

PMID 42720293
阅读全文 →
PubMedTropical doctor2026-09-10

Vaccine hesitancy in peripheral communities: Combating digital malpractice.

Siddiqui Gulnaz Fatima GF, Siddiqui Shahid Akhtar SA

PMID 42720454
阅读全文 →
PubMedCureus2026-09-10

Recurrent Mumps in a Fully Vaccinated Young Adult With a Prior Breakthrough Infection: A Case Report.

Ramadugu Rithika R, Pidikiti Chandra Varshini CV, Cordero Peña Alesha A, Almonte Angelis A et al.

Mumps is a vaccine-preventable viral disease that typically presents with parotid gland swelling and constitutional symptoms. Although widespread immunization has substantially reduced disease incidence, outbreaks continue to occur among vaccinated populations, raising concerns regarding waning immunity and vaccine failure. Recurrent mumps following both prior natural infection and complete vaccination is uncommon and remains infrequently reported. We describe a 21-year-old woman who presented with a four-day history of fever, malaise, myalgia, and progressive painful swelling of the left parotid gland associated with difficulty chewing and speaking. She had received two doses of measles-mumps-rubella (MMR) vaccine according to the national immunization schedule and had a documented history of mumps infection at nine years of age, occurring after she had already completed her two-dose MMR series (vaccine-breakthrough infection). Physical examination revealed tender unilateral parotid enlargement, cervical lymphadenopathy, and evidence of undernutrition with a body mass index of 16.7 kg/m². Laboratory evaluation demonstrated iron deficiency anemia. Further evaluation, including positive mumps RT-PCR and positive anti-mumps IgM serology, confirmed acute mumps infection, while investigations excluded alternative causes of parotid enlargement. The patient was managed conservatively with isolation, supportive care, nutritional supplementation, and symptomatic treatment, resulting in complete clinical recovery without complications. This case highlights that recurrent mumps can occur despite prior natural infection and complete MMR vaccination. Although waning immunity and host factors such as undernutrition may have contributed to susceptibility, a causal relationship cannot be established from a single case. Continued surveillance and awareness of breakthrough infections remain important, particularly in resource-limited settings.

PMID 42719503
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多rabies vaccine